Antibody titers after a third dose of the SARS-CoV-2 BNT162b2 vaccine in immunocompromised adults in Greece: Is a fourth dose necessary?그리스의 면역 저하 성인에서 SARS-CoV-2 BNT162b2 백신 3차 접종 후 항체 역가: 4차 접종이 필요한가요?Article Published on 2022-10-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] age anti-S Anti-spike antibody Antibody titers Autoimmune autoimmune diabete autoimmune diabetes Autoimmune disease average baseline BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine BNT162b2 vaccine change correlated COVID-19 Decline decrease diabetes dose Effectiveness fold Fold change Fold changes Greece humoral Humoral response IgG antibody titer IgG antibody titers IgG GMC Immunocompromised immunocompromised adult immunocompromised adults immunocompromised individual immunocompromised individuals immunogenicity Inflammatory inflammatory disease leukemia lymphoma mRNA of BNT162b2 Omicron variant Omicron variants postvaccination real-world data SARS-CoV-2 serum sample serum samples Sex significantly the SARS-CoV-2 the vaccine third dose. vaccination Vaccine vaccine dose vulnerable population [DOI] 10.1002/jmv.27954 PMC 바로가기 [Article Type] Article
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trialChAdOx1 nCoV-19 또는 BNT162b2 2회 접종 및 BNT162b2(COV-BOOST) 3차 접종 후 4차 접종으로 제공된 BNT162b2 및 mRNA-1273 COVID-19 백신의 안전성, 면역원성 및 반응성: 다기관, 맹검, 단계 2, 무작위 시험Clinical Trial Published on 2022-08-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 1:1 95% CI adverse event All participants analysed anti-spike protein IgG assigned blinded block size BNT162b2 boost booster Booster vaccine cellular Cellular and humoral immunity Cellular immune response ChAdOx1 nCoV-19 computer-generated Concentration Controlled trial country COV-BOOST COVID-19 COVID-19 vaccine COVID-19 vaccines dose doses Effectiveness ELISA ELISPOT Endpoint enrolled fatigue female Fold change Fold changes force geometric geometric mean groups Humoral immunity immunogenicity Intramuscular injection IQR ISRCTN Laboratory Local male median age median interval Moderna modified intention-to-treat mRNA mRNA-1273 mRNA-1273 booster mRNA-1273 COVID-19 vaccine multicentre of BNT162b2 outcome participant peak per-protocol population Pfizer-BioNTech Phase 2 random randomisation list randomised controlled trial Randomised trial Randomly reactogenicity receive Registered reported representing response Safety SARS-CoV-2 screened Serious Adverse Event seronegative participant seronegative participants serostatus Seven significant increase statistician T-cell Response T-cell responses Task Force the vaccine the vaccines titre treatment allocation Trial upper arm Vaccine variant were assessed wild-type [DOI] 10.1016/S1473-3099(22)00271-7 PMC 바로가기 [Article Type] Clinical Trial
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 InfectionSARS-CoV-2 감염의 자가 보고된 신경학적 후급성 후유증이 있는 사람들의 신경학적 손상 및 염증의 혈장 표지자Article Published on 2022-06-142022-09-11 Journal: Neurology® neuroimmunology & neuroinflammation [Category] COVID19(2023년), MERS, SARS, 바이오마커, [키워드] 95% CI absolute levels Acidic acute infection acute respiratory syndrome acute respiratory syndrome coronavirus biologic CNS Cohort coronavirus correlated correlation correlations defined demonstrated early recovery elevated Elevation elevations examined exhibited Fold change Fold changes GFAp greater identify immune activation immunologic marker individuals Infection Inflammation inflammatory pathway initial Injury interleukin interleukin 6 Intervention involved less light chain linear marker mechanism mixed-effects model monocyte monocyte chemoattractant protein 1 Necrosis neurologic not differ PASC Prevent primary clinical outcome Protein Recovery time reported respiratory SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 Symptom Symptoms treat Tumor tumor necrosis tumor necrosis factor tumor necrosis factor α [DOI] 10.1212/NXI.0000000000200003 PMC 바로가기 [Article Type] Article
GraphOmics: an interactive platform to explore and integrate multi-omics data그래픽학 : 다중 생물 데이터를 탐색하고 통합하는 대화식 플랫폼Software Published on 2021-12-182022-09-10 Journal: BMC Bioinformatics [Category] 유전자 메커니즘, [키워드] Analysis biochemical can be used case study Clustering common reaction complex complexity computational method Data exploration dataset demonstrated difficulty examined filtered Fold changes heatmap hypothese Hypothesis information mapped metabolomics Omics integration p values pathway Pathway analysis Pathways performed platform proteomics reaction Reactions Reactome Result selected statistical significance Support transcriptomics user Visualisation was used while [DOI] 10.1186/s12859-021-04500-1 PMC 바로가기 [Article Type] Software
GraphOmics: an interactive platform to explore and integrate multi-omics dataSoftware Published on 2021-12-182022-10-27 Journal: BMC Bioinformatics [Category] Coronavirus, Fulltext, [키워드] Analysis biochemical can be used Clustering common reaction complex computational method Data exploration dataset demonstrated examined filtered Fold changes heatmap hypothese Hypothesis information mapped metabolomics Omics integration pathway Pathway analysis Pathways performed platform proteomics reaction Reactome Result selected statistical significance Support transcriptomics user Visualisation was used while [DOI] 10.1186/s12859-021-04500-1 PMC 바로가기 [Article Type] Software
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination델타의 중화 감소 (B.1.617.2) 예방 접종 후 SARS-COV-2 우려 변형Research Article Published on 2021-12-022022-08-13 Journal: PLoS Pathogens [Category] Biochemistry, SARS, 변종, 진단, [키워드] (Beta accumulation African antibody Antibody titre antigenic antigenic drift antigenic profiles assessment Astra Zeneca Author B.1.351 B.1.617.1 B.1.617.2 bat bats Beta BNT162b2 BNT162b2 vaccines Booster vaccine booster vaccines ChAdOx1 changes in collected COVID-19 COVID19 death decrease decreases Delta delta variant dose effective Effectiveness Efficacy elicited evade expressed facilitate fold Fold changes glycoprotein groups hospitalisation Human human cell human cells humans Immunity India indicated individual Infection Lineage magnitude Mutation neutralisation neutralise Neutralising Antibodies neutralising antibody titres of BNT162b2 Pfizer Pfizer/BioNTech Prevent profile protective immune response pseudoviruses recipient recipients reduced reduction reduction in reductions reductions in required risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus sensitivity sera Severe infection shape significantly higher South South Africa spike glycoprotein spike glycoproteins Spike protein subsequent the spike protein titre vaccinated individuals vaccination Vaccine vaccine efficacy Vaccines variant variant B.1.617.2 variants variants of concern Viral viral variant Viral variants virus Virus spike VOCs while with infection with infections Wuhan Wuhan, China [DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article
Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities다양한 질병 중증도를 가진 COVID-19 환자의 계절성 인간 코로나바이러스에 대한 교차 반응성 체액성 면역 반응Article Published on 2021-10-012022-09-11 Journal: International Journal of Infectious Diseases [Category] SARS, 치료기술, 치료법, [키워드] 229E addition Admission analyzed antibody Antibody titer association C-reactive protein collected convalescence coronavirus correlations COVID-19 COVID-19 patient cross-reactive antibody cross-reactivity disease disease severity early phase enzyme enzyme-linked immunosorbent assays evaluated Fold change Fold changes HCoV HCoV-HKU1 HCoV-NL63 HCoV-OC43 HCoVs HKU1 human coronavirus Human coronavirus humoral immune response IgG antibodies IgG antibody increases in Japan Lactate lactate dehydrogenase lymphocyte Mild mild cases NL63 no difference nucleocapsid OC43 OD value OD values optical optical density patients with COVID-19 Protein SARS-CoV-2 seasonal human coronavirus. serum sample serum samples Severe case severe cases Significant significant differences [DOI] 10.1016/j.ijid.2021.08.026 PMC 바로가기 [Article Type] Article
Syndromic Surveillance Insights from a Symptom Assessment App Before and During COVID-19 Measures in Germany and the United Kingdom: Results From Repeated Cross-Sectional AnalysesOriginal Paper Published on 2020-10-092022-10-31 Journal: JMIR mHealth and uHealth [Category] COVID-19, MERS, [키워드] added analysis analyzed assessment association chi-square test collected complement Concentration conducted consequence country COVID-19 COVID-19 lockdown COVID-19 measures COVID-19 symptom assessment apps Descriptive analysis difference digital public health diminished Effect epidemiological Epidemiology female Fold change Fold changes generate Germany Health health effects of COVID-19 measures, infoveillance Hyposmia hypothese implementation implication Implications Infection insight introduced less limitation lockdown majority measure Measures memory mental health mitigate objective p value participatory epidemiology participatory surveillance Pearson performed proportion public health real time reported Result self-reported symptom sense of taste Spread statistically significant Stress Surveillance surveillance data Symptom symptom checker apps symptomatic Syndromic surveillance the mean unique United Kingdom variables [DOI] 10.2196/21364 PMC 바로가기 [Article Type] Original Paper